DynamX Bioadaptor, a Unique “Uncaging” Platform for Coronary Artery Revascularisation: Ongoing Clinical Results From the DynamX Hong Kong Registry

Abstract

Drug-eluting stents (DES) are the current mainstay in treatment and have reduced major adverse cardiac events (MACE) in the first year after PCI. Beyond 1 year, a 2%–3% annualised event rate without plateau is observed. The DynamX™ Coronary Bioadaptor System is a 71 μm cobalt-chromium platform with a novel “uncaging” mechanism of circumferential rings, which maintains the axial links between the rings following uncaging. Conventional metallic DES “cage” the artery, inhibit positive adaptive remodelling and vasomotion, and cause geometric distortion. These factors likely contribute to the persistent increase in annual MACE rate. The DynamX Bioadaptor combines acute performance of contemporary DES and unique benefits of arterial “uncaging”, allowing positive adaptive remodelling and restoring compliance and geometry. In previously reported clinical trials results, the DynamX Bioadaptor has shown excellent clinical safety and lumen maintenance and Bioadaptor growth not seen with DES.